Cargando…
Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has no...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878318/ https://www.ncbi.nlm.nih.gov/pubmed/20526359 http://dx.doi.org/10.1371/journal.pone.0010865 |
_version_ | 1782181852642017280 |
---|---|
author | Huang, Xin van den Berg, Anke Gao, Zifen Visser, Lydia Nolte, Ilja Vos, Hans Hepkema, Bouke Kooistra, Wierd Poppema, Sibrand Diepstra, Arjan |
author_facet | Huang, Xin van den Berg, Anke Gao, Zifen Visser, Lydia Nolte, Ilja Vos, Hans Hepkema, Bouke Kooistra, Wierd Poppema, Sibrand Diepstra, Arjan |
author_sort | Huang, Xin |
collection | PubMed |
description | BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has not been previously investigated. METHODOLOGY/PRINCIPAL FINDINGS: We randomly selected 145 cHL patients with formalin-fixed, paraffin embedded tissue blocks available from 5 hospitals from the Northern part of China. Hematoxylin & Eosin-stained slides were used to reclassify the histological subtypes according to the WHO classification. EBV status was determined by visualization of EBERs in tumor cells using in situ hybridization. Membranous expression of HLA molecules was detected by immunohistochemistry using antibodies HC-10 (class I heavy chain) and anti-ß2-microglobulin for HLA class I, and CR3/43 for HLA class II. EBV+ tumor cells were observed in 40% (58/145) of the cHL patients. As expected, the percentage of EBV+ cases was much higher in the mixed cellularity subtype (71%) than in the nodular sclerosis subtype (16%) (p<0.001). Expression of HLA class I was observed in 79% of the EBV+ cHL cases and in 30% of the EBV- cases (p<0.001). For HLA class II, 52% of EBV+ cHL cases were positive, compared to 43% in EBV- cases (p = 0.28). CONCLUSIONS: The results in the Northern China population were similar to those in the Caucasian population for HLA class I, but not for HLA class II. |
format | Text |
id | pubmed-2878318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-28783182010-06-04 Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients Huang, Xin van den Berg, Anke Gao, Zifen Visser, Lydia Nolte, Ilja Vos, Hans Hepkema, Bouke Kooistra, Wierd Poppema, Sibrand Diepstra, Arjan PLoS One Research Article BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has not been previously investigated. METHODOLOGY/PRINCIPAL FINDINGS: We randomly selected 145 cHL patients with formalin-fixed, paraffin embedded tissue blocks available from 5 hospitals from the Northern part of China. Hematoxylin & Eosin-stained slides were used to reclassify the histological subtypes according to the WHO classification. EBV status was determined by visualization of EBERs in tumor cells using in situ hybridization. Membranous expression of HLA molecules was detected by immunohistochemistry using antibodies HC-10 (class I heavy chain) and anti-ß2-microglobulin for HLA class I, and CR3/43 for HLA class II. EBV+ tumor cells were observed in 40% (58/145) of the cHL patients. As expected, the percentage of EBV+ cases was much higher in the mixed cellularity subtype (71%) than in the nodular sclerosis subtype (16%) (p<0.001). Expression of HLA class I was observed in 79% of the EBV+ cHL cases and in 30% of the EBV- cases (p<0.001). For HLA class II, 52% of EBV+ cHL cases were positive, compared to 43% in EBV- cases (p = 0.28). CONCLUSIONS: The results in the Northern China population were similar to those in the Caucasian population for HLA class I, but not for HLA class II. Public Library of Science 2010-05-28 /pmc/articles/PMC2878318/ /pubmed/20526359 http://dx.doi.org/10.1371/journal.pone.0010865 Text en Huang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Huang, Xin van den Berg, Anke Gao, Zifen Visser, Lydia Nolte, Ilja Vos, Hans Hepkema, Bouke Kooistra, Wierd Poppema, Sibrand Diepstra, Arjan Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients |
title | Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients |
title_full | Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients |
title_fullStr | Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients |
title_full_unstemmed | Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients |
title_short | Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients |
title_sort | expression of hla class i and hla class ii by tumor cells in chinese classical hodgkin lymphoma patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878318/ https://www.ncbi.nlm.nih.gov/pubmed/20526359 http://dx.doi.org/10.1371/journal.pone.0010865 |
work_keys_str_mv | AT huangxin expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT vandenberganke expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT gaozifen expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT visserlydia expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT nolteilja expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT voshans expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT hepkemabouke expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT kooistrawierd expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT poppemasibrand expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients AT diepstraarjan expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients |